Prima BioMed Net Income 2006-2020 | IMMP

Prima BioMed net income from 2006 to 2020. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Prima BioMed Annual Net Income
(Millions of US $)
2021 $-22
2020 $-9
2019 $-13
2018 $-10
2017 $-7
2016 $-45
2015 $-27
2014 $-11
2013 $-13
2012 $-21
2011 $-21
2010 $-11
2009 $-2
2008 $-2
2007 $-2
2006 $-3
2005 $-5
Prima BioMed Quarterly Net Income
(Millions of US $)
2020-12-31
2017-03-31 $-2
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-06-30
2010-06-30
2009-06-30
2008-06-30
2007-06-30
2006-06-30
2005-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.243B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81